Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury
R ecent evidence has revealed that angiotensin (Ang) II plays important roles not only in blood pressure control but also in cardiovascular remodeling, insulin resistance, and regulation of water retention. 1, 2 Arterial neointimal thickening is a critical process in the development of atherosclerosis, bypass graft failure, and restenosis after angioplasty. Since the AT 1 receptor is a major subtype of Ang II receptors, direct vascular effects caused by Ang II, such as vasoconstriction, inflammation, vascular remodeling, and thrombosis, are mediated by the AT 1 receptor. [2] [3] [4] Thus, blockade of AT 1 receptor function appears to be important for the treatment of cardiovascular disease. ACE inhibitors and AT 1 receptor blockers (ARB) are widely used to inhibit the function of the renin-angiotensin system in clinical practice. ARB specifically block Ang II binding to the AT 1 receptor and thereby Ang II may preferentially stimulate unbound the AT 2 receptor, another Ang II receptor subtype, which could act antagonistically against the function of the AT 1 receptor. 5, 6 In contrast, blockade of Ang II production by ACE inhibitors is not complete, since Ang II can also be produced by chymase in humans. 7, 8 However, ACE inhibitors increase the bradykinin level through the inhibition of kininase and thus activate the kallikrein-kinin system. 9 The increase in bradykinin elevates prostacyclin production, eNOS activity, and nitric oxide (NO) production. 10, 11 Thus, the increase in bradykinin induces various actions, such as vasodilation, anticoagulation, hypotension, and cardiovascular inflammatory changes. 11 In the present study, to explore the implication of bradykinin and NO in the action of ACE inhibitors on vascular remodeling, we examined the effect of imidapril, an ACE inhibitor, on inflammatory vascular injury induced by polyethylene-cuff placement. To confirm that ACE inhibitors have beneficial actions independent of blockade of Ang II production, we used AT 1 a-receptor-deficient mice and examined the effect of imidapril on vascular remodeling.
Methods

Animals
Adult male AT 1 aKO mice (based on C57BL/6J strain and donated by Tanabe Seiyaku Co, Ltd, Osaka, Japan) and wild-type mice (C57BL/ 6J; age, 10 to 12 weeks; weight, 25 to 30g) were used in this study. The mice were housed in a room in which lighting was controlled (12 hours on, 12 hours off) and room temperature was kept at 25°C. They were given a standard diet (MF, Oriental Yeast Co, Ltd) and water ad libitum. The experimental protocol was approved by the Animal Studies Committee of Ehime University. Inflammatory vascular injury was induced by polyethylene cuff placement around the femoral artery according to methods described previously, 12, 13 and morphometric analysis to measure neointimal area was performed as previously described. 13 Imidapril (donated by Tanabe Seiyaku Co, Ltd) was administered by gavage at a dose of 1 mg/kg per day in 0.5% carboxymethylcellulose sodium solution from the day of cuff placement. TA606 (donated by Tanabe Seiyaku Co, Ltd) was administered intraperitoneally with an osmotic minipump from the day of cuff placement. L-NAME (20 mg/kg per day; Funakoshi) was also administered orally, and Hoechst 140 (100 g/kg per day; Peptide Institute, Inc) was administered intraperitoneally with an osmotic minipump from the day of cuff placement. Blood pressure was measured by the indirect tail-cuff method with a blood pressure monitor (MK-1030, Muromachi Kikai Co, Ltd).
Immunohistochemical Staining
Monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor (TNF-␣) were stained by the streptavidin-biotin-peroxidase method with the use of formalin-fixed, paraffin-embedded sections, as described previously. 5, 13 Proliferating cell nuclear antigen (PCNA) was stained with the use of an MOM immunodetection kit (Vector Laboratories, Inc) with anti-PCNA monoclonal antibody (Novocastra Laboratories, Ltd). The PCNA labeling index was calculated as the percentage of PCNA-positive nuclei in total cell nuclei.
Reverse Transcription-Polymerase Chain Reaction
Cuffed arteries at 7 days after cuff placement and control intact arteries were pooled (nϭ8, 10 for each group, respectively). RNA was prepared with the use of TRIzol reagent (GIBCO-BRL), and RT-PCR was performed as described previously. 5,13 PCR primers were designed for MCP-1, TNF-␣, AT 1 receptor, AT 2 receptor, ACE, and GAPDH, as reported previously. 5,11 PCR primers for AT 1 b receptor are 5Ј-GCATCATCTTTGTGGTGGG-3Ј (forward) and 5Ј-ATGAGGACATCCAGAAAAC-3Ј (reverse).
Western Blot Analysis
Total proteins were prepared from pooled arteries at 7 days after cuff placement (nϭ6 to 8 for each group), and Western blotting was performed as previously described. 5 
Determination of Tissue cGMP Content
Artery samples were obtained at 7 days after cuff placement, quickly frozen in the liquid nitrogen, and stored at Ϫ80°C until use. Pooled samples (nϭ5) were homogenized in 6%(wt/vol) tetrachloroacetic acid solution and centrifuged, and the supernatant was used to measure cGMP with an RIA kit (Amersham Pharmacia Biotech), according to the manufacturer's protocol.
Statistical Analysis
Values are expressed as meanϮSEM in the text and figures. The data were analyzed by means of 2-way ANOVA. If a statistically significant effect was found, post hoc analysis was performed to detect the difference between the groups. A value of PϽ0.05 was considered statistically significant.
Results
Effect of the ACE Inhibitor Imidapril on Neointimal Formation and Cell Proliferation After Cuff Placement in WT and AT 1 aKO Mice
As previously reported, polyethylene cuff placement induced neointimal formation in mice. 5, 13, 14 In AT 1 a-receptor-deficient (AT 1 aKO) mice, neointimal formation 14 days after operation was significantly less than that in wild-type (WT) mice ( Figure 1 ). Imidapril inhibited neointimal formation by Ϸ60% in WT mice at a dose of 1 mg/kg per day, which did not change blood pressure (data not shown). The inhibitory effect of imidapril on neointimal formation was smaller but significant in AT 1 aKO mice (Figure 1 ). PCNA labeling index, a marker of cell proliferation, was also significantly lower in AT 1 aKO mice and was decreased by imidapril in the intima and media of both strains (Figure 1) . To assess the possible involvement of blockade of AT 1 b receptor in the inhibitory action of imidapril, we examined the effect of the AT 1 -receptor blocker TA606 on neointima formation after cuff placement in AT 1 aKO mice (Figure 2 ). Treatment with TA606 at a dose of 1 mg/kg per day significantly reduced neointimal formation in WT mice without affecting the blood pressure, but it showed no significant effect in AT 1 aKO mice. After cuff placement, expression of the AT 1 a receptor, AT 1 b receptor, AT 2 receptor, and ACE was increased ( Figures 3A  and 3B ). The increases in ACE and AT 2 receptor were not significantly different in WT and AT 1 aKO mice ( Figures 3A  and 3B ). On the other hand, expression of AT 1 b receptor was very low in femoral artery and not changed after cuff placement ( Figure 3A) .
Effect of Imidapril on Inflammatory Response Induced by Cuff Placement in WT and AT 1 aKO Mice
The inflammatory response, such as expression of MCP-1 and TNF-␣, was determined by RT-PCR, Western blot, and 
Effects of Hoechst140 and L-NAME on Inhibitory Action of Imidapril on Vascular Injury After Cuff Placement
To examine the potential roles of bradykinin and NO in the vascular protective effect of imidapril, a bradykinin B2 receptor blocker, Hoechst140, or an NO synthase inhibitor, L-NAME, was administered with imidapril. As shown in Figure 9 , treatment with Hoechst140 antagonized the inhibitory effect of imidapril on neointimal formation after cuff placement in WT mice. Hoechst140 caused 80% recovery of neointimal formation inhibited by imidapril ( Figure 9 ). Similar antagonism by L-NAME was also observed (Figure 9 ). In AT 1 aKO mice, Hoechst140 or L-NAME totally abolished the inhibitory action of imidapril on neointimal formation after cuff placement ( Figure 9 ). This dose of either Hoechst140 or L-NAME did not significantly affect the area of neointima in WT as well as AT 1 aKO mice. Treatment with Hoechst140 or L-NAME attenuated the effect of imidapril on expression of MCP-1 and TNF-␣ after cuff placement. RT-PCR and/or Western blotting showed that recovery of MCP-1 and TNF-␣ was inhibited by imidapril in both WT and AT 1 aKO mice (Figure 4 ). These effects of Hoechst140 and L-NAME were also observed in immunohistochemical studies (Figures 5 through 8) . Figure 10 shows the content of cGMP in the femoral artery after cuff placement. cGMP content was slightly decreased after cuff placement and significantly increased by the treatment with imidapril. This increase in cGMP content by imidapril was attenuated by L-NAME (Figure 10 ).
Discussion
In the present study, to examine the potential role of the bradykinin-NO system in the effects of ACE inhibitors on neointimal formation and inflammatory responses in vascular injury induced by cuff placement, we studied the effects of imidapril on vascular remodeling by using AT 1 aKO mice, in which the actions of major part of AT 1 receptor are genetically omitted. Imidapril inhibited cell proliferation and neo- intimal formation as well as inflammatory responses, such as expression of MCP-1 and TNF-␣, in the injured artery. However, these inhibitory actions of imidapril were observed not only in WT mice but also in AT 1 aKO mice. Moreover, the inhibitory actions of imidapril were significantly attenuated by Hoechst140 and L-NAME, inhibitors of the bradykinin B2 receptor and NO synthase, respectively. These results indicate that the inhibitory effect of imidapril on vascular injury was at least partly mediated through stimulation of the bradykinin-NO system.
Ang II plays an important role in hemodynamic control, cardiovascular function, atherosclerotic changes, and insulin resistance. 2, 15 Major functions of Ang II, such as vasoconstriction, cell growth, antiapoptosis, and induction of inflammatory factors, are mediated through the AT 1 receptor. 1, 2, 16 One of the advantages of ACE inhibitors appears to be the increase in bradykinin level followed by stimulation of NO synthesis. 10, 11, 17 In our study, imidapril inhibited neointimal formation, proliferation of vascular smooth muscle cells, and inflammatory responses induced by cuff placement. These effects of imidapril appear to be independent of its hemodynamic action, because the dose of imidapril used in our study did not affect the systemic blood pressure (data not shown). As previously described, the inhibitory action of ACE inhibitor, imidapril, appears to be caused mainly by a reduction of AT 1 -receptor-mediated signaling through the blockade of Ang II production. 10 In fact, neointimal formation and perivascular inflammation were significantly unmarked in Figure 6 . Effects of imidapril, Hoechst140, and L-NAME on immunohistochemical detection of MCP-1 in injured artery after cuff placement in AT 1 aKO mice. Immunohistochemical staining of MCP-1 was performed at 7 days after cuff placement as in Figure 5 . A, Control; B, imidapril (1 mg/kg per day); C, imidaprilϩHoechst140 (100 g/kg per day); D, imidaprilϩL-NAME (20 mg/kg per day). Magnification ϫ200. AT 1 aKO mice. However, imidapril inhibited neointimal formation, DNA synthesis, and inflammatory responses also in AT 1 aKO mice. These observations indicate that the effects of imidapril are due to not only the inhibition of Ang II production but also other factors. Previous studies have suggested that the bradykinin-NO system plays an important role in the action of ACE inhibitors on cardiovascular remodeling. 17, 18 Thus, we examined the involvement of the bradykinin-NO system in the action of imidapril by using AT 1 aKO mice.
In our study, the inhibitory effects of imidapril on neointimal formation and perivascular inflammation were attenuated Ϸ80% by a bradykinin-receptor antagonist, Hoechst 140, in WT mice ( Figure 9 ). This result indicates that bradykinin was at least partly involved in the action of imidapril on vascular remodeling after cuff placement. It is reported that NO is an important mediator of the vasoactive action of bradykinin. 9, 10 In our study, administration of an NO-synthase inhibitor, L-NAME, also attenuated the action of imidapril to a similar extent to Hoechst 140 ( Figure 9) . Moreover, the content of cGMP, an intracellular messenger of NO, in the femoral artery was significantly increased by treatment with imidapril, and this increase of cGMP was inhibited with L-NAME ( Figure 10 ). These results suggest the involvement of the bradykinin-NO system in the action of imidapril on cuff-induced vascular injury. Figure 7 . Effects of imidapril, Hoechst140, and L-NAME on immunohistochemical detection of TNF-␣ in injured artery after cuff placement in WT mice. Immunohistochemical staining of MCP-1 was performed 7 days after cuff placement as in Figure  5 . A, Control; B, imidapril (1 mg/kg per day); C, imidaprilϩHoechst140 (100 g/kg per day); D, imidaprilϩL-NAME (20 mg/kg per day). Magnification ϫ200. Involvement of bradykinin and NO in action of imidapril on neointimal formation after cuff placement in WT and AT 1 aKO mice. Cuff placement was performed and crosssectional areas of media and neointima were measured as in Figure 1 . Imidapril, 1 mg/kg per day; Hoe, Hoechst140, 100 g/kg per day; L-NAME, 20 mg/kg per day. nϭ7 to 8 for each group. *PϽ0.05 vs control, §PϽ0.01 vs imidapril (ϩ). Values are meanϮSEM. Figure 10 . Effects of imidapril and L-NAME on tissue cGMP content in injured artery after cuff placement. Artery samples were prepared at 7 days after cuff placement and Western blotting was performed as described in the Methods section. Values are meanϮSEM of measurements with 3 pooled samples. *PϽ0.01 vs without cuff, §PϽ0.05 vs cuff with imidapril.
